v3.26.1
Revenues (Details)
$ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Dec. 31, 2021
USD ($)
Component
PerformanceObligation
Aug. 31, 2025
DAWNZERA [Member]        
Revenues [Abstract]        
Age of pediatric patients approved to use medicine       12 years
WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]        
Revenues [Abstract]        
Upfront payment received (in Dollars)     $ 200  
Number of material components (in Component) | Component     4  
Number of performance obligations (in PerformanceObligation) | PerformanceObligation     1  
Transaction price (in Dollars)     $ 200  
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca   55.00%    
Percentage of costs for development activities intended solely to support U.S. regulatory approvals paid by AstraZeneca 75.00%      
Percentage of costs for development activities intended to support global regulatory approvals paid by AstraZeneca 87.50%